Front page
Nothing from your lists
What covered companies filed with the SEC, day by day.
Nothing from your lists
+ 23 more
Nothing from your lists
Park Dental Partners, Inc. · “As previously reported, on August 28, 2026 , Park Dental Partners, Inc. (“Company”) identified unauthorized access to its computer network.”¶1
EON Resources Inc. · “As a result, management of the Company determined on October 8, 2026 that the Company’s 2025 Form 10-K filed with the SEC on September 28, 2026 (the “Affected Period”) should no longer be relied upon.”¶1
LogicMark, Inc. · “Merger Sub merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent.”¶1
Nothing from your lists
Nothing from your lists
Nothing from your lists
Nothing from your lists
On August 28, 2026, Park Dental Partners identified unauthorized access to its computer network, and the investigation determined data was subject to unauthorized acquisition.¶1
The Company has identified impacted patients whose protected health information was involved and is completing notifications under applicable state and federal law.¶1
The Company is aware of four state court putative class actions related to the August 2026 data breach, the first filed on September 3, 2026, in Ramsey County, Minnesota.¶2¶3
On October 7, 2026, plaintiffs filed a motion to consolidate the four actions and appoint interim lead class counsel, and the Company intends to vigorously defend its positions.¶3
To date, the Company has not identified any material impact on its financial condition or results of operations as a result of this incident, including the current expected legal and advisor cost.¶4
On September 23, 2026, the Lessors delivered default notices under the CJ3 Leases, and on October 1, 2026, the Lessors terminated the leases and retook the CJ3 Aircraft.¶1¶2
The Lessors claim approximately $514,557 due under the CJ3 Leases, including the accelerated Principal Balance, accrued interest and unpaid rent.¶3¶4
On October 2, 2026, management committed to a reduction in force that reduces the workforce from 42 to 37 employees, or approximately 12%.¶5¶6
On October 6, 2026, Vincent Monteparte resigned as Chairman of the Board and as a director, effective immediately, with no severance or other payments.¶7¶8
On October 8, 2026, the Board appointed Kyle McCollum as a director to fill the vacancy and elected him Chairman of the Board, effective immediately.¶9¶10¶11
The Board of Nephros, Inc. set Wednesday, November 25, 2026, at 11:00 a.m., Eastern Time, as the date of the 2026 Annual Meeting of Stockholders, to be held virtually via live webcast.¶1
The Board set the close of business on September 30, 2026 as the record date for stockholders entitled to notice of and to vote at the 2026 Annual Meeting.¶1
Rule 14a-8 stockholder proposals and Rule 14a-19 director nominee notices must be received by the Company no later than the close of business on October 23, 2026.¶2¶3
The date of the 2026 Annual Meeting changed by more than 30 days from the anniversary of the 2025 Annual Meeting held on June 16, 2025, so the deadlines in the 2025 proxy statement no longer apply.¶4
EON Resources determined an error in depletion, depreciation and amortization expense for the fourth quarter of fiscal 2025, and its 2025 Form 10-K filed September 28, 2026 should no longer be relied upon.¶2¶1
Depletion, depreciation and amortization expense for fiscal 2025 was overstated by $3,540,000 and the net loss decreased by $2,632,000.¶1
The reported loss allocated to shareholders for fiscal 2025 is expected to be reduced from $10.1 million to approximately $7.5 million in an amended 2025 Form 10-K.¶1
The restatement is non-cash and will have no impact on the Company’s cash flows or cash, cash equivalents and marketable investments.¶1
Mesa Laboratories approved a Restructuring Program on October 6, 2026, to focus Clinical Genomics on pharmacogenomics, oncology and high-utilization accounts, and it expects to eliminate approximately 40 positions.¶1¶2
The company estimates total pre-tax charges of approximately $2.6 million to $3.4 million, primarily in the second half of fiscal year 2027, with related cash expenditures of approximately $2.9 million to $3.7 million.¶3
The Savings Plan is expected to reduce annualized operating costs by approximately $9.3 million, with approximately $4.3 million reinvested for a net annualized cost reduction of approximately $5.0 million.¶4¶5
The company will report second quarter fiscal year 2027 results on November 9, 2026, and provide fiscal year 2027 guidance reflecting the Savings Plan.¶6
On October 13, 2026, under the Merger Agreement dated July 31, 2026, Merger Sub merged with and into LogicMark, Inc., which survived as a wholly owned subsidiary of Langham Project LLC.¶2¶1¶3
Each outstanding share of common stock, other than dissenting shares, was converted into the right to receive $1.31 per share in cash, without interest and subject to applicable withholding taxes.¶3¶4
Vested restricted stock units and options were cashed out at the Per Share Merger Consideration, unvested restricted stock units were canceled without consideration, and outstanding warrants were exercised, redeemed, canceled or otherwise terminated.¶5¶6¶7
On October 7, 2026, directors Carine M. Schneider, Barbara K. Gutierrez, Robert A. Curtis and John Pettitt resigned from the Board, effective that date, not due to any disagreement with the Company.¶8
Certificates of withdrawal terminated the Series G, Series C and Series J preferred stock designations, filed on October 9, 2026 and October 13, 2026, with no such shares outstanding.¶9
On October 7, 2026, the Board approved the dismissal of Lao Professionals as the Company’s independent registered public accounting firm, effective October 7, 2026.¶1¶2
Lao advised the Company that it is transitioning its audit clients whose principal executive offices are in California to U.S.-based independent registered public accounting firms.¶3
Lao’s report on the fiscal years ended December 31, 2025 and 2024 contained no adverse opinion or disclaimer, but included a going concern explanatory paragraph.¶4
The Board approved Simon & Edward, LLP of Rowland Heights, California, as the new independent registered public accounting firm for fiscal 2026 and the quarter ending September 30, 2026.¶5
Management concluded internal control over financial reporting was not effective as of December 31, 2025, citing material weaknesses in segregation of duties, governance and oversight, and documentation.¶6¶7
On October 9, 2026, Adia Med, Inc. fully repaid and discharged its unsecured revolving line of credit facility originally entered into on June 30, 2024, with Larry Powalisz, its Chief Executive Officer, as lender.¶1
The facility had been increased over time to a commitment of $1,000,000 and bore interest at 6% per annum calculated daily.¶2
The Company paid the Lender $500,000 on October 7, 2026, and $434,970.94 on October 9, 2026, for a total of $934,970.94, of which $74,658.94 was accrued interest.¶3¶4¶5
The Lender acknowledged that the outstanding principal balance and all accrued interest under the facility have been paid in full as of October 9, 2026.¶6
As of closing, $250.0 million was borrowed under the term loan facility and $150.0 million under the revolving credit facility, and proceeds with cash on hand repaid the Existing Credit Agreement.¶1
In connection with the new agreement, the Borrower repaid in full all outstanding obligations under and terminated its Credit Agreement dated as of January 2, 2025, with MidCap Financial Trust as administrative agent.¶2
The term loan facility will amortize in equal quarterly installments of $3.125 million, commencing with the fiscal quarter ending March 31, 2027, with the remaining balance payable on the maturity date.¶3
The company announced on October 13, 2026 that the new facilities are priced at Term SOFR plus 1.50% to 2.50%, compared to the prior rate of SOFR plus 4.50% to 5.25%.¶4
On October 9, 2026, Cavitation Technologies and Alchemy Beverages entered into definitive tender offer agreements with BrightFlixx Finance (Luxembourg) S.A., replacing agreements with European Guarantee Services.¶2¶3
BrightFlixx intends to commence a cash tender offer for all CVAT shares for $35 million in cash, less Company liabilities, and a cash tender offer for Alchemy shares for $7 million in cash, less Alchemy liabilities.¶4¶5
The Company terminated its August 14, 2026 tender offer agreement with EGS on October 8, 2026, and did not pay a termination fee or any form of compensation to EGS.¶6¶7
The tender offers have not commenced, and the CVAT offer is subject to conditions including a valid tender of at least 90% of outstanding shares and CFIUS regulatory approval or a no further action determination.¶8¶9
On September 30, 2026, Interactive Strength Inc. exchanged Remainder Notes with an aggregate outstanding amount of $7,685,090 for 768,509 shares of Series R Convertible Preferred Stock, and the notes were cancelled.¶1¶2¶3
The Company agreed to reimburse the Holders $50,000 for legal fees and expenses and to reserve 100% of the maximum number of common shares issuable upon conversion of the Series R Shares.¶4
On October 1, 2026, Wattbike substantially completed a refinancing of its prior working capital facility, providing for aggregate financing of up to £1,375,000 (approximately $1,825,200) across three financings.¶5¶6¶7¶8
In connection with the repayment of the Prior Facility, Wattbike paid the Prior Lender an exit fee of £85,000 (approximately $112,800).¶9
On September 30, 2026, the board approved a Certificate of Designations designating 768,509 shares of Series R Preferred Stock with a stated value of $10 per share and a conversion price of $2.83.¶10¶11
On October 6, 2026, Ghost Management Group, LLC agreed with Alameda Square Owner LLC to terminate its lease for approximately 113,692 rentable square feet at 767 S. Alameda Street, Los Angeles, effective October 7, 2026, after a third-party tenant contingency was satisfied.¶1¶2
The Subsidiary agreed to pay the landlord a termination fee of $32.4 million, payable in fifty-three monthly installments beginning October 2026.¶3
On October 9, 2026, the Subsidiary entered into a lease with 7th and SM LP for approximately 26,223 rentable square feet at 924 E. 7th Street, Austin, Texas, with estimated base rent of approximately $14.3 million over the term.¶4
The Austin Landlord will provide a tenant improvement allowance of up to approximately $1.7 million, and the Subsidiary will provide a letter of credit or cash security deposit of approximately $0.8 million.¶4
On October 9, 2026, Copley Acquisition Corp and Ignite Proteomics, LLC entered into a Mutual Termination of Business Combination Agreement, terminating their Business Combination Agreement effective immediately.¶1
Under the Termination Agreement, no party has further rights or obligations under the Business Combination Agreement, except specified surviving sections, and each party will bear its own expenses.¶2
Copley intends to continue to pursue a business combination and currently has until November 2, 2026, to consummate one, subject to extension under its organizational documents.¶3
On October 12, 2026, VisionWave Holdings, Inc. and parties including Sadot Group Inc. entered into a letter agreement terminating the JV Agreement, with no termination penalty or break fee payable by any party.¶1¶2
CM advised the Company that it is unable to produce the financial statements required by the JV Agreement, and as of the Effective Date Sadot had not funded any portion of the Capital Commitment.¶3¶4
All 7,814,323 units of CMJV held by Sadot were cancelled for no consideration, and the Company will issue Sadot 500,000 shares of its common stock as VisionWave Consideration Shares.¶5¶6
The VisionWave Consideration Shares will be issued in a private placement under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, with no underwriting discounts or commissions paid.¶7
On October 12, 2026, the Board declared a dividend of one purchase right for each outstanding share of Class A common stock, payable to stockholders of record as of the close of business on October 22, 2026.¶1
Each right entitles its holder, once exercisable, to purchase one one-thousandth of a share of Series B Preferred Stock at an exercise price of $15.00 per Unit, subject to adjustment.¶1
The rights become exercisable after a person becomes an Acquiring Person, defined as a beneficial owner of 19.9% or more of the outstanding Common Stock, subject to certain exceptions.¶2¶3
The rights will expire at the close of business on October 11, 2027, unless earlier redeemed or exchanged by the Company.¶4
Before the earlier of the tenth business day after an Acquiring Person announcement or the Final Expiration Date, the Board may redeem the rights at a price of $0.001 per Right.¶5
Strive filed a certificate of amendment with the Nevada Secretary of State establishing a minimum sale price of $100.00 per share for all future sales of SATA by the Company.¶1
The amendment redefined Business Day to no longer exclude Saturday or Sunday, to provide for daily dividends on those days to the extent permitted in the future.¶2¶3
On October 13, 2026, the board maintained the regular dividend rate on SATA at 13.00% per annum, effective for periods commencing on or after November 1, 2026.¶4
The board declared daily cash dividends of $0.0571, or $1.0849 in the aggregate for the full monthly period, per share of SATA for November 1, 2026 through November 30, 2026.¶5
Capstone Holding Corp. completed its change of state of incorporation from Delaware to Nevada effective 12:01 a.m. Pacific Time on October 9, 2026, by merging into its Nevada wholly owned subsidiary.¶1
Each outstanding share of the Predecessor's common stock was automatically converted into one outstanding share of Capstone NV common stock, par value $0.0005 per share, with no action required by shareholders.¶2
The Articles of Incorporation and Bylaws of Capstone NV in effect before the Effective Time became the governing documents, and shareholder rights are now governed by the Nevada Revised Statutes.¶3
Stockholder rights differ in some respects from those under Delaware law and the Predecessor's charter documents, as described in the October 1, 2025 Proxy Statement.¶4
On October 9, 2026, Boxlight, the Series D Majority Holders and J.J. Astor executed and delivered a revised Consent, Waiver and Ratification, effective as of September 30, 2026, replacing the Original Series D Consent in its entirety.¶1¶2
The revised consent extends consent to the Series E CoD itself, narrows the most-favored-nation waiver to voting rights, and removes consent to register the Series E Conversion Shares.¶3¶4¶5
The Series E Preferred Stock may not be converted until the earlier of no Series D Preferred Stock remaining outstanding or an effective resale registration statement with Required Stockholder Approvals obtained.¶6
Michael Pope, Chairman of the Board and Chief Executive Officer of J.J. Astor, executed the acknowledgment of the Revised Series D Consent on behalf of J.J. Astor.¶7
On October 9, 2026, CID HoldCo, Inc. closed its acquisition of Envoy Technologies, Inc. from BladeRanger Ltd., and Envoy became a wholly owned subsidiary.¶1¶2
At the Closing the Company issued BladeRanger 233,543 shares of Common Stock and 8,433,123 shares of Series C Preferred Stock for all 135 outstanding shares of Envoy common stock.¶2¶3
The Envoy Convertible Note held by Blink was not converted at Closing and will convert into 2,166,667 shares of Common Stock once the Blink Conversion Conditions are satisfied.¶4¶5¶6
The Company filed a Certificate of Designation for Series C Convertible Non-Redeemable Preferred Stock with a stated value of $6.00 per share and an initial conversion price of $6.00 per share.¶7¶8¶9
Alaunos completed its business combination with Velaris Therapeutics on October 13, 2026, issuing 105,286 shares of Series B and 33,054 shares of Series C non-voting convertible preferred stock to Velaris stockholders.¶1¶2
Alaunos agreed to sell 687,789 shares of Common Stock at $1.4357 per share and 243,063 shares of Series C Preferred Stock at $1,435.70 per share, for an aggregate purchase price of approximately $350 million, with closing expected October 14, 2026.¶3¶4
Peter Harwin was appointed to the Board effective immediately after the Second Merger, and three directors will resign upon stockholder approval of the Conversion Proposal, with Lead Investor designees filling the vacancies.¶5¶6
Alaunos will repurchase its Existing Preferred Stock for cash equal to liquidation value plus accrued dividends, approximately $1.6 million if stockholder approval is obtained prior to February 2027.¶7
Clarivate completed the sale of its Life Sciences and Healthcare business to an affiliate of Altaris, LLC on October 6, 2026, for an aggregate purchase price of $600 million.¶1
Clarivate received approximately $488.4 million in cash at close, along with a $75.0 million unsecured senior note and $25.0 million of deferred cash consideration.¶1¶2
Approximately $20.0 million of non-recurring transaction costs were incurred and are not reflected in historical results, and will be classified within discontinued operations.¶3
Clarivate will use $488.4 million of closing cash proceeds and $11.6 million of company cash for partial redemptions of notes, and will provide transition services to Altaris for one to 12 months.¶4¶5
